

## DAFTAR PUSTAKA

- Abdullah, M. I., Junit, S. M., Ng, K. L., Jayapalan, J. J., Karikalan, B., dan Hashim, H. O. (2019) 'Papillary thyroid cancer genetic alterations and molecular biomarker investigations', *International journal of medical sciences*, 16(3), pp450–460.
- Agarwal, S., Chand, G., Jaiswal, S., Mishra, A., Agarwal, G., Agarwal, A., Verma, A. K., dan Mishra, S. K (2011) 'Pattern and risk factors of central compartment lymph node metastasis in papillary thyroid cancer' a prospective study from an endocrine surgery centre. *Journal of thyroid research*, 2012, pp1-7.
- Ali, H. H., Ibraheem, M. H. dan Alhindawi, M. M. (2018). 'Immunohistochemical expression of matrix metalloproteinase-9 in urothelial carcinoma of urinary bladder'. *Kasr al ainy medical journal*, 24(3), pp109-114.
- Amalinei, C., Caruntu, I. D., Giuşca, S. E., dan Balan, R. A. (2010) 'Matrix metalloproteinases involvement in pathologic conditions'. *Rom j morphol embryol*, 51(2), pp.215-228.
- Anderson, C. dan McLaren, K. M. (2005) 'Endocrine tumors'. *Tumor siagnosis practical approach and pattern analysis*. 2nd ed. London: Hodder Arnold, pp349-52.
- Angulo, J. C., Ferruelo, A., Rodriguez-Barbero, J., Nunez, C., de Fata, F., dan Gonzalez, J. (2011) 'Detection and molecular staging of bladder cancer using real-time RT-PCR for gelatinases (MMP-2, MMP-9) and TIMP-2 in peripheral blood'. *Acta urologicas espanolas*, 35(3), pp127-36.
- American Cancer Society. Cancer facts and figures 2017. (2017) Available from: <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf>
- Ariza, N.M., Juan P. B. (2018) 'Management of low-risk papillary thyroid cancer'. *Endocrinology and metabolism*, 33(2), pp185-194.
- Arora, A., Tolley, N., dan Tuttle, M. (2010) 'Pathological spectrum of thyroid disease'. *A Practical manual of thyroid and parathyroid diseases*. New York-USA: Wiley-Blackwell pp14-24.
- Asare, E. A., Brierley, J. D., Byrd, D. R. (2017) 'Endocrine system'. *AJCC cáncer staging manual*. 8th ed. Chicago: Springer, pp880-882.

- Bu, R., Siraj, A. K., Divya, S. P., Kong, Y., Parvathareddy, S. K., Al-Rasheed, M., Al-Kuraya, K. S. (2017) 'Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in middle eastern papillary thyroid cancer'. *International journal of cancer*, 142(10), pp2028–2039.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R., Torre, L. dan Jemal, A. (2018) 'Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality world wide for 36 cancers in 185 countries', *Ca cancer j clin*, 68(6), pp394–424. doi: 10.3322/caac.21492.
- Carling, T., dan Udelsman, R. (2014) 'Thyroid cancer'. *The annual review of medicine*, 65, pp125–137. doi:10.1146/annurev-med-061512-105739.
- Chan, J. K. (2013) 'Tumors of the thyroid and parathyroid glands'. Fletcher, C. D., (ed) *Diagnostic histopathology Of tumors volume 1*. 4th (edn). Philadelphia: Elsevier, pp1177-1272.
- Charoenrat, P., Rhys-Evans dan Eccles, S. A. (2001) 'Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of head and neck'. *Arch otolaryngol head and neck surgery*, 127(7), pp813-20.
- Chen, P. S., Shih, Y. W., Huang , H. C., dan Cheng, H. W. (2011) 'Diosgenin, a steroidal saponin, inhibits migration and invasion of human prostate cancer PC-3 Cells by Reducing Matrix Metalloproteinases Expression'. *Plos on*, 6(5), pp1-9. doi:10.1371/journal.pone.0020164.
- Cojoc, M., Peitzsch, C., Trautmann, F., Polishchuk, L., Telegeev, G. D., dan Dubrovskaya, A. (2013) 'Emerging targets in cancer management: role of the CXCL12/CXCR4 axis'. *Oncotargets and therapy*, 6, pp1347–1361. doi:10.2147/ott.s36109.
- Dayer, R., Babashah, S., Jamshidi, S., Sadeghizadeh, M. (2018) 'Upregulation of CXC chemokine receptor 4-CXC chemokine ligand 12 axis in invasive breast carcinoma: A potent biomarker predicting lymph node metastasis', *J Can res ther*, 14(2), pp345-350.
- Domanska, U. M., Kruizinga, R. C., Nagengast, W. B., Timmer-Bosscha, H., Huls, G., De Vries, E. G. E., dan Walenkamp, A. M. E. (2013) 'A review on CXCR4/CXCL12 axis in oncology: No place to hide', *European journal of cancer*. Elsevier Ltd, 49(1), p219–230. doi: 10.1016/j.ejca.2012.05.005.
- Furusato B, Mohamed A, Uhlen M, Rhim JS. (2010) 'CXCR4 and cancer'. *Pathology international*, 60(7), pp497-505.

- Gauhar, T. M., Chaudary, A., Maqbool, H. M., Azim, A., Afzal, A., Alam, K. M., Ahmed, A., dan Azim, K. M. (2014) 'Papillary thyroid carcinoma'. *Thyroid disorders & therapy*, 3(1), pp1-3.
- González, H. E., Leiva, A., Tobar, H., Böhmwald, K., Tapia, G., Torres, J., Mosso, L., Bueno, S. M., Gonzalez, P., Kalergis, A. M., dan Riedel, C. A. (2009) 'Altered chemokine receptor expression in papillary thyroid cancer'. *Thyroid*, 19(9), pp957-965.
- Guo, F. Wang., Y. Mok., S. Xue., F. dan Zhang, W. (2016) 'CXCL12/CXCR4 a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks a Review'. *Oncogene* 35(7):816-26.
- Hamdani C, Maria FH, Nurjati CS. (2012) 'Patologi molekuler'. Jakarta: Badan Penerbit FKUI pp140-7.
- Hao, L., Zhang, C., Qiu, Y., Wang, L., Luo, Y., Jin, M., Zhang, Y., Guo, T., Matsushima, K., Zhang, Y. (2007) 'Recombination of CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in human breast cancer'. *Cancer letters*, 253(1), pp34-42.
- Hay, I. D., Thompson, G. B., Grant, C. S., Bergstralh, E. J., Dvorak, C. E., Gorman, C. A., Bergstralh, E., Dvorak, C., Gorman, C., Maurer, M., McIver, B., Mullan, B., Oberg, A., Powell, C., Heerden, J., Goellner, J. R. (2002). 'Papillary thyroid carcinoma managed at the mayo clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients'. *World journal of surgery*, 26(8), pp879-885. doi: 10.1007/s00268-002-6612-1.
- He, X., Wei, Q., Zhang, X., Xiao, J., Jin, X., Zhu, Y., Cui, B., dan Ninga, G. (2010) 'Immunohistochemical expression of CXCR4 in thyroid carcinomas and thyroid benign lesions'. *Pathology – research and practice*, 206(10), pp712-715.
- Hiller, D., Chu, Q.D. (2011) 'CXCR4 and axillary lymph nodes: review of potential biomarker for breast cancer metastasis', *International Journal of Breast Cancer*, 2011, pp.1-6.
- Hsieh, S.-H., Chen, S.-T., Hsueh, C., Chao, T.-C., dan Lin, J.-D. (2012) 'Gender-specific variation in the prognosis of papillary thyroid cancer TNM stages II to IV'. *International Journal of Endocrinology*, 2012, pp1-5.
- Hua, H., Li, M., Luo, T., Yin, Y., dan Jiang, Y. (2011) 'Matrix metalloproteinases in tumorigenesis: an evolving paradigm'. *Cellular and Molecular Life Sciences*, 68(23), pp3853-3868.

- Hwang, T.L., Iee, L. Y., Wang, C. C., Liang, Y., Huang, S. F., dan Wu, C. M. (2010) 'Claudin-4 expression is associated with tumor invasion, MMP-2 and MMP-9 expression in gastric cancer'. *Experimental and therapeutic medicine*, 1(5), pp789-797.
- Insilla, A. C., Agnese P., Nicla, B., Elisabeta M., Cristina N., Paolo V., Paolo M., dan Fulvio B. (2018) 'TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases'. *Oncology letters*, 15(3), pp1763-2770.
- Israël, A. (2010) 'The IKK complex, a central regulator of NF- $\kappa$ B activation'. *Cold Spring Harbor perspectives in biology*, 2(1) a000158, pp1-14. doi: 10.1101/cshperspect.a000158.
- Jeon, M. J., dan Shong, Y. K. (2018) 'Metastatic lymph node characteristics predicting prognosis of papillary thyroid cancer patients'. *Annals of thyroid*, 3(6), pp1-2. doi:10.21037/aot.2018.06.01.
- Jin, W.X. Jin., Y. X., Ye, D. R., Zheng, Z. C., Sun, Y. H., Zhou, X. F., Li, Q., Wang, O.C., Liu, H. G., dan Zhang, X. H. (2018) 'Predictive factors of skip metastasis in papillary thyroid cancer'. *Medical science monitor*, 3(24), pp2744-2749. doi:10.12659/MSM.907357.
- Jiang, W. G., Sanders, A. J., Katoh, M., Ungefroren, H., Gieseler, F., Prince, M., Thompson, S., Zollo, M., Spano, D., Dhawan, P., Silva, D., Subbarayan, P., Santini, D. (2015). 'Tissue invasion and metastasis: molecular, biological and clinical perspectives'. *Seminars in cancer biology*, 35, ppS244–S275.
- Karakoc, D., dan Ozdemir, A. (2010) 'Lymph node surgery in papillary thyroid carcinoma'. *Int surg*, 95(2), pp142-146.
- Khan, A. (2009) 'Tumor of thyroid gland : non C cell tumors'. *Surgical pathology of endocrine and neuroendocrine tumors*. Totowa: Humana Press, pp41-81.
- Khosravi, M. H., Kouhi, A., Saeedi, M., Bagherihagh, A., Hosein, M. (2017) 'Thyroid cancer: considerations, classifications and managements'. In: Z. Akarslan, ed. *Diagnosis and management of head and neck cancer*. Croatia: InTech, pp. 57-82.
- Kumar, V., Abbas, A. K., dan Aster, J. C. (2018) 'Endocrine system'. *Robbins basic pathology*. 10th ed. Philadelphia: Elsevier, pp755-764.
- Kumar, V.H dan Hasan O.B. (2017) ' Clinical relevance of MMP-9 in terms of neoplasm growth, invasion and metastasis in thyroid, breast and colorectal cancer'. *International surgery journal*, 4(12), pp4049-4053.

- Liao, Y. X., Zhou, C. H., Zeng, H., Zou, D. Q., Wang, Z. Y., Yin, F., dan Hua, Y. Q. (2013) 'The role of the CXCL12-CXCR4/CXCR7 axis in the progression and metastasis of bone sarcomas (Review)'. *International journal of molecular medicine*, 32(6), pp1239-1246.
- Liang, Huasheng ; Zhong, Yuhua ; Luo, Zuojie; Huang , Yu ; Lin, Huade ; Luo, Min ; Zhan, Song ; Xie, Kaiqing ; Ma, Yan ; Quentin, Q (2010). 'Assessment of biomarkers for clinical diagnosis of papillary thyroid carcinoma with distant metastasis'. *The international journal of biological markers*, 25(1), pp38-45.
- Liu, X., Su, C., Xu, J., Zhou, D., Yan, H., Li, W., Chen, G., Zhang, N., Xu, D., dan Hu, H. (2018) 'Immunohistochemical analysis of matrix metalloproteinase-9 predicts papillary thyroid carcinoma prognosis'. *Oncology letters*, 17(2), pp2308-2316. doi:10.3892/ol.2018.9850.
- Liu, R., Bishop, J., Zhu, G., Zhang, T., Ladenson, P. W., dan Xing, M. (2017) 'Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer'. *JAMA oncology*, 3(2), pp202-208. doi:10.1001/jamaoncol.2016.3288.
- Liu, W., Cheng, R., Su, Y., Diao, C., Qian, J., Zhang, J., Ma, Y., dan Fan, Y. (2017) 'Risk factors of central lymph node metastasis of papillary thyroid carcinoma'. *Medicine*, 96(43), pp1-7. doi:10.1097/md.00000000000008365.
- Lloyd, R. V., Buehler, D., dan Khanafshar, E. (2011) 'Papillary thyroid carcinoma variants'. *Head and neck pathol*, 5(1), pp51-56.
- Lin, Y. Ma, Q., Li, L. & Wang, H. (2018) 'The CXCL12/CXCR4 axis promotes migration, invasion and EMT in human papillary thyroid carcinoma B-CPAP cells via NF- $\kappa$ B signaling'. *Biochemistry cell biology*, 96(5), pp619-626.
- Luo, D., Chen, H., Li, X., Lu, P., Long, M., Peng, X., Lin, S., Tan, L., Ouyang, N., dan Li, H. (2017) 'Activation of the ROCK1/MMP-9 pathway is associated with the invasion and poor prognosis in papillary thyroid carcinoma'. *International journal of oncology*, 51(4), pp1209-1218.
- Meng, X., Tebo, H. Zhang, Q., Pang, R., Zheng, G., dan Song, D. (2012) 'Expression and clinical significance of matrix metalloproteinase 9 (MMP9) papillary thyroid carcinomas'. *African journal of pharmacy and pharmacology*, 6(44), pp3075-3079.
- Naoum, G. E., Morkos, M., Kim, B., dan Arafat, W. (2018) 'Novel targeted therapies and immunotherapy for advanced thyroid cancers'. *Molecular cancer*, 17(1), pp1-15. doi:10.1186/s12943-018-0786-0.

- Orbach, G. O. (2016) 'Risk stratification in differentiated thyroid cancer: An ongoing process'. *Rambam maimonides med j*, 7(1) e0003, pp1-9. doi:10.5041/RMMJ.10230.
- Penna, G. C., Vaisman, F., Vaisman, M., Sobrinho-Simões, M., dan Soares, P. (2016) 'Molecular markers involved in tumorigenesis of thyroid carcinoma: focus on aggressive histotypes'. *Cytogenetic and genome research*, 150(3-4), pp194–207. doi:10.1159/000456576.
- Pusdatin (2015) *Infodatin 2015*. Jakarta. <https://pusdatin.kemkes.go.id>.
- Qu, H.-J., Qu, X.-Y., Hu, Z., Lin, Y., Wang, J.-R., Zheng, C.-F., dan Tan, Z. (2017) 'The synergic effect of BRAFV600E mutation and multifocality on central lymph node metastasis in unilateral papillary thyroid carcinoma'. *Endocrine journal*, 65(1), pp113–120. doi:10.1507/endocrj.ej17-0110.
- Rahbari, R., Zhang, L., dan Kebebew, E. (2010) 'Thyroid cancer gender disparity'. *Future oncology*, 6(11), pp1771–1779.
- Rosai, J., dan Tallini, G., (2011) 'Thyroid gland'. Houston, M, (ed). *Surgical pathology*. 10th edn. New York: Elsevier, pp504-514.
- Rosai J., Albares Saavedra J., Asioli S, Baloch Z.W., Bogdanova T., Chen H., Delellis R.A., Erickson L.A., Fagin J.A., Franssila K., Giordano T. J., Hay I. D., Kato R., Lloyd R. V., Mete O., Nikiforov Y. E., Piana S., Prasad M. L., Sadow P., Schneider A. B., Soares P., Sobrinho Simoes M., Vielh P., Wenig B.M. (2017) 'Papillary thyroid carcinoma'. *WHO classification of tumours of endocrine organs*. IARC.pp81-91.
- Sak, S. D. (2015) 'Variants of papillary thyroid carcinoma: multiple faces of a familiar tumor'. *Turkish journal of pathology*, 31(Suppl):34-47). doi:10.5146/tjpath.2015.01313.
- Sobolik, T., Su, Y., Wells, S., Ayers, G. D., Cook, R. S., & Richmond, A. (2014). 'CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways'. *Molecular biology of the cell*, 25(5), pp566-82.
- Shin, D. Y., Kim, K. J., Ku, C. R., Lee, M. K., Jee, S. I., Chung, W. Y., dan Lee, E. J. (2013) 'Different CXCR4 expression according to various histologic subtype of papillary thyroid carcinoma'. *Endocrine pathology*, 24(4), pp169–176. doi:10.1007/s12022-013-9259-6.
- Sticker, T.P. dan Kumar, V., (2010) 'Neoplasia'. *Robbins pathology basic of disease*, 8th edn, Saunders: Philadelphia, p.259-330.

- Sun, W., Lan, X., Zhang, H., Dong, W., Wang, Z., He, L., Zhang, T., dan Liu, S. (2015) 'Risk factors for central lymph node metastasis in CNO papillary thyroid carcinoma: a systematic review and meta-analysis'. *Plos one*, 10(10) e0139021, 1-17. doi:10.1371/journal.pone.0139021.
- Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J. (2010) 'CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression'. *Cancer metastasis rev*, 29(4), pp709-22.
- Tallon, P., Holt, E., Callender, G., Cheng, D., dan Deshpande, H. (2014) 'Management of papillary thyroid cancer: an overview for the primary care physician'. *Jcomjournal*, 21(5), pp233-240.
- Teicher, B. A., dan Fricker, S. P. (2010) 'CXCL12 (SDF-1)/CXCR4 pathway in cancer'. *Clinical cancer research*, 16(11), pp2927–2931. doi:10.1158/1078-0432.ccr-09-2329.
- Torregrossa, L., Giannini, R., Borrelli, N., Sensi, E., Melillo, R. M., Leocata, P., Materazzi, G., Miccoli, P., Santoro, M., dan Basolo, F. (2011) 'CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas'. *Modern pathology*, 25(1), pp46–55. doi:10.1038/modpathol.2011.140.
- Vasko, V. V., dan Saji, M. (2007) 'Molecular mechanisms involved in differentiated thyroid cancer invasion and metastasis'. *Current opinion in oncology*, 19(1), pp11–17. doi:10.1097/cco.0b013e328011ab86.
- Vasala, K., Paakko, P. dan Turpeenniemi-Hujanen, T., (2008) 'Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis'. *Anticancer research*, 28(3B), pp.1757-1761.
- Vasavada, D. dan Dholakia, A. (2013) 'Matrix metalloproteinases: do you know them?' *Int J Res Med*, 2(2), pp203-206.
- Wang, L. Y., dan Ganly, I. (2016) 'Nodal metastases in thyroid cancer: prognostic implications and management'. *Future oncology*, 12(7), pp981–994.
- Xu, C., Zhao, H., Chen, H., Yao, Q. (2015) 'CXCR4 in breast cancer: oncogenic role and therapeutic targeting', *Drug Design, Development and therapy*, 9, pp,4953–4964. doi: 10.2147/DDDT.S84932.
- Yasuoka, H., Kodama, R., Hirokawa, M., Takamura, Y., Miyauchi, A., Sanke, T., dan Nakamura, Y. (2008) 'CXCR4 expression in papillary thyroid carcinoma: induction by nitric oxide and correlation with lymph node metastasis'. *BMC cancer*, 8:274, pp1-8. doi:10.1186/1471-2407-8-274.

Zuo, J., Wen, M., Li, S., Lv, X., Wang, L., Ai, X., & Lei, M. (2017). 'Overexpression of CXCR4 promotes invasion and migration of non-small cell lung cancer via EGFR and MMP-9'. *Oncology letters*, 14(6), pp7513–7521.